Genervon Biopharmaceuticals LLC
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01854294
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Columbia Medical Center NY, New York, New York, United States
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01850381
- Locations
- 🇺🇸
Columbia University Medical Center/NY Presbyterian Hospital, New York, New York, United States
Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Genervon Biopharmaceuticals, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01221246
- Locations
- 🇺🇸
UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center), Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Huntington Memorial Hospital Stroke Center, Pasadena, California, United States